Clearbridge Small Cap Growth Strategy Added Dyne Therapeutics (DYN) in Q4

What: Clearbridge Small Cap Growth Strategy added Dyne Therapeutics (DYN) in Q4 2025.
Why: The fund manager likely chose DYN due to its innovative gene therapy treatments.
Signal: This move suggests the fund is optimistic about DYN's growth prospects.
Target: The fund's Q4 2025 holdings now total around $**15.5 billion**.
Risk: Investors should consider DYN's high R&D expenses and regulatory risks.